New outsourcing demand is reported to be emerging in Japan's life sciences BPO market, driven by clinical trial reform and progress in international drug development.
The view was presented that promoting clinical trial reform and increased activity in international drug development will expand outsourcing demand in Japan's life sciences BPO market.
The article does not identify specific companies or provide figures, but points to the possibility of greater outsourcing of clinical trial-related activities and externalization of development processes.